Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine.  The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s written decision is anticipated in the coming months. Also Read: FDA Delays ‘Important’ Moderna Vaccine Review: William Blair Says 2025 Growth, ‘2026 Breakeven Story’ Depends On It. Moderna is actively pursuing legal action against Pfizer and BioNTech in courts across Europe and the United States, claiming that the Comirnaty vaccine infringes on two patents.  In response, Pfizer and BioNTech ...